EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY 4.0

Adverse outcomes in patients with atrial fibrillation and a pacemaker: a cohort study

Vincent Meier iD, Stefanie Aeschbacher iD, Michael Coslovsky iD, Andreas Gasser iD, Rebecca E Paladini iD, Tobias Reichlin iD, Nicolas Rodondi iD, Andreas Müller iD, Jürg Beer iD, Giulio Conte iD, Giorgio Moschovitis iD, Julia Bardoczi iD und 10 weitere

Europace · 2025

DOI: 10.1093/europace/euaf275 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Europace, 2025. Verfasst von Vincent Meier und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University Hospital Basel, Petersgraben 4, Basel 4031, Switzerland. Hauptthemen laut MEDLINE: Atrial Fibrillation, Pacemaker, Artificial, Heart Failure, Cardiac Pacing, Artificial. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Science Foundation, Swiss Heart Foundation, University of Basel.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Patients with atrial fibrillation (AF) are at a high risk of adverse cardiovascular outcomes. Little is known about the specific population of AF patients with implanted pacemaker (PM) and their prognosis. Therefore, we aimed to compare the risks of adverse outcomes in AF patients with and without PM. Methods and results Data from two Swiss prospective, multicentre cohort studies (Swiss-AF, Beat-AF) (n = 3675) with yearly follow-ups (FUs) up to 8 years were analysed. The first main outcome was major adverse cardiovascular events (MACE), a composite of stroke or transient ischaemic attack, myocardial infarction, cardiovascular death, and systemic embolism. The second main outcome was hospitalization for heart failure (HF). Secondary outcomes were the individual components of MACE. We performed time-updated Cox regression analyses to investigate the association of PM and outcomes. Median age was 71.4 years, 28.8% female, 445 (12.1%) patients had a PM at baseline, and 238 additional patients (7.4%, 1.05%/year) received a PM over a median FU of 7 years. Patients with a PM had higher incidence rates for MACE and HF (5.97 and 5.08 per 100 patient-years, respectively), compared to patients without a PM (3.37 and 2.61 per 100 patient-years, respectively). After multivariable adjustment, we found no independent association of PM and MACE (aHR [95% CI] 1.12 [0.95–1.33; P = 0.183]) or HF (aHR [95% CI] 1.14 [0.94–1.37; P = 0.180]). We found consistent results for the individual components of MACE.

Conclusion

Patients with AF and a PM experienced an increased rate of adverse cardiovascular outcomes. However, the PM itself was not independently associated with these outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationPacemaker, ArtificialHeart FailureCardiac Pacing, ArtificialHumansFemaleMaleAgedSwitzerlandProspective StudiesRisk FactorsMiddle AgedHospitalizationIncidenceTreatment OutcomeAged, 80 and overTime FactorsStrokeIschemic Attack, TransientRisk AssessmentMyocardial InfarctionProportional Hazards ModelsEmbolism

Stichwörter der Autor:innen

Adverse outcomesAtrial fibrillationMACEPacemaker

Autor:innen und Institutionen

  • Department of Cardiology, University Hospital Basel, Petersgraben 4, Basel 4031, Switzerland.
  • Cardiovascular Research Institute Basel, University Hospital Basel, Spitalstrasse 2, Basel 4056, Switzerland.
  • Department of Clinical Research, University of Basel, University Hospital Basel, Basel, Switzerland.
  • Department of Cardiology Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Department of General Internal Medicine Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.

ORCID-Profile: Vincent Meier, Stefanie Aeschbacher, Michael Coslovsky, Andreas Gasser, Rebecca E Paladini, Tobias Reichlin, Nicolas Rodondi, Andreas Müller, Jürg Beer, Giulio Conte, Giorgio Moschovitis, Julia Bardoczi, Alain Bernheim, Elia Rigamonti, Christine S Zuern, Felix Mahfoud, Christian Sticherling, David Conen, Stefan Osswald, Michael Kühne, Philipp Krisai

Förderung

  • Swiss National Science Foundation
  • Swiss Heart Foundation
  • University of Basel
  • Roche Diagnostics
  • Boehringer Ingelheim
  • Sanofi-Aventis
  • Merck Sharp & Dome
  • Bayer

Zitieren

APA

Meier, V., Aeschbacher, S., Coslovsky, M., Gasser, A., Paladini, R. E., Reichlin, T., Rodondi, N., Müller, A., Beer, J., Conte, G., Moschovitis, G., Bardoczi, J., Bernheim, A., Rigamonti, E., Möri, L., Zuern, C. S., Mahfoud, F., Sticherling, C., Conen, D., …, & Krisai, P. (2025). Adverse outcomes in patients with atrial fibrillation and a pacemaker: a cohort study. Europace. https://doi.org/10.1093/europace/euaf275

Vancouver

Meier V, Aeschbacher S, Coslovsky M, Gasser A, Paladini RE, Reichlin T, et al. Adverse outcomes in patients with atrial fibrillation and a pacemaker: a cohort study. Europace. 2025. doi:10.1093/europace/euaf275

BibTeX
@article{Meier2025,
  author = {Meier, Vincent and Aeschbacher, Stefanie and Coslovsky, Michael and Gasser, Andreas and Paladini, Rebecca E and Reichlin, Tobias and Rodondi, Nicolas and Müller, Andreas and Beer, Jürg and Conte, Giulio and Moschovitis, Giorgio and Bardoczi, Julia and Bernheim, Alain and Rigamonti, Elia and Möri, Laura and Zuern, Christine S and Mahfoud, Felix and Sticherling, Christian and Conen, David and Osswald, Stefan and Kühne, Michael and Krisai, Philipp},
  title = {Adverse outcomes in patients with atrial fibrillation and a pacemaker: a cohort study},
  journal = {Europace},
  year = {2025},
  doi = {10.1093/europace/euaf275}
}
Kostenlos starten →